Relationship of changes in total hip bone mineral density to vertebral and nonvertebral fracture risk in women with postmenopausal osteoporosis treated with once-yearly zoledronic acid 5 mg: The HORIZON-Pivotal Fracture Trial (PFT) (Q61970837)

From Wikidata
Jump to navigation Jump to search
scientific article published on 17 July 2012
edit
Language Label Description Also known as
English
Relationship of changes in total hip bone mineral density to vertebral and nonvertebral fracture risk in women with postmenopausal osteoporosis treated with once-yearly zoledronic acid 5 mg: The HORIZON-Pivotal Fracture Trial (PFT)
scientific article published on 17 July 2012

    Statements

    title
    Relationship of changes in total hip bone mineral density to vertebral and nonvertebral fracture risk in women with postmenopausal osteoporosis treated with once-yearly zoledronic acid 5 mg: the HORIZON-Pivotal Fracture Trial (PFT) (English)
    1 reference
    stated in
    Europe PubMed Central
    PubMed ID
    22532515
    reference URL
    https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22532515%20AND%20SRC:MED&resulttype=core&format=json
    retrieved
    29 January 2020

    Identifiers

     
    edit
      edit
        edit
          edit
            edit
              edit
                edit
                  edit
                    edit
                      Retrieved from "https://www.wikidata.org/w/index.php?title=Q61970837&oldid=2118212813"